DPN inhibits the expression of genes regulating vascularization in MCL. (A) DPN inhibits expression of VEGF-C, LYVE-1, CD34, and angiogenin mRNA in Granta-519 MCL tumors. (B-D) The number of VEGF-C–positive cells, as determined by immunostaining (B), the number of LYVE-1-positive lymphatic vessels (C), and the size of the lymphatic vessels, as determined by immunostaining (D), were decreased in DPN-treated Granta-519 MCL lymphomas compared with control. Each group consisted of 5 mice. For vehicle vs DPN: *P < .05, **P < .01, and ***P < .001. Data are representative of 3 independent experiments.